ReviewCurrent treatment options in oncology2023
Update of Diagnosis and Targeted Therapy for ALK
Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Inflammatory myofibroblastic tumors of the colon in pediatrics: clinical presentation, management, and outcomes-A case report and systematic review of literature.International journal of colorectal disease · 2025Pooled it
- A Phase 1 Study to Assess the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Healthy Adults.Clinical pharmacology in drug development · 2026Trial
- Management of Inflammatory Myofibroblastic Tumor of Urinary Bladder With Partial Cystectomy: A Case Report.Cureus · 2026Article
- Inflammatory myofibroblastic tumour: unravelling the interplay of inflammation, kinase signalling, and therapeutic resistance.Frontiers in oncology · 2026Review
- Gastric inflammatory myofibroblastic tumor in adults: a case report and literature review.Frontiers in oncology · 2026Article
- Case Report: Synchronous ALK-positive laryngeal inflammatory myofibroblastic tumor and EGFR-mutant lung adenocarcinoma in a child.Frontiers in pediatrics · 2026Article
- Renal inflammatory myofibroblastic tumor: a case report.Frontiers in oncology · 2026Article
- Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboringFrontiers in oncology · 2026Article
- Reactive Nodular Fibrous Pseudotumor Presenting as Gastric Outlet Obstruction in a Young Adult Male Patient: A Case Report and Review of the Medical Literature.Case reports in pathology · 2026Article
- Case Report: Urachal inflammatory myofibroblastic tumor with bladder invasion.Frontiers in oncology · 2026Article
- Case Report:Frontiers in oncology · 2026Article
- Inflammatory myofibroblastic tumor on second portion of duodenum: a case report.Korean journal of clinical oncology · 2025Article
- Clinical features analysis of inflammatory myofibroblastic tumors of the retroperitoneal and genitourinary system.BMC urology · 2025Article
- Clinical management and long-term outcomes in pulmonary inflammatory myofibroblastic tumor: a 12-Year experience with 14 surgically treated adult patients at a single center.World journal of surgical oncology · 2025Article
- A case report of retroperitoneal leiomyosarcoma originating from the right ovarian vein and invading the right renal vein and inferior vena cava.The Journal of international medical research · 2025Article
- ALK Inhibition in a Patient with Inflammatory Myofibroblastic Tumor Harboring CARS1-ALK Fusion.Cancer research and treatment · 2025Article
- ALK in cancer: from function to therapeutic targeting.Nature reviews. Cancer · 2025Review
- Clinical diagnosis and treatment of abdominal inflammatory myofibroblastic tumors.Discover oncology · 2025Article
- Mesenteric inflammatory myofibroblastic tumor (IMT), a rare neoplasm in a pediatric patient: imaging findings and literature review.Journal of ultrasound · 2025Review
- Clinicopathological Features and Immunochemical Staining of Inflammatory Myofibroblastic Tumor: A Retrospective Study of 48 Cases.Analytical cellular pathology (Amsterdam) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OPINION STATEMENT: Inflammatory myofibroblastic tumor (IMT), characterized by intermediate malignancy and a propensity for recurrence, has presented a formidable clinical challenge in diagnosis and treatment. Its pathological characteristics may resemble other neoplasms or reactive lesions, and the treatment was limited, taking chemotherapies as the only option for those inoperable. However, discovering anaplastic lymphoma kinase (ALK) protein expression in approximately 50% of IMT cases has shed light on a new diagnostic approach and application of targeted therapies. With the previous success of combating ALK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.